Implementation of pre-clinical methodologies to study fibrosis and test anti-fibrotic therapy.

Autor: Oakley F; Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK., Gee LM; Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK., Sheerin NS; Renal Department, Freeman Hospital, Newcastle upon Tyne, UK; Applied Immunobiology and Transplantation Research Group, Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, UK., Borthwick LA; Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. Electronic address: lee.borthwick@ncl.ac.uk.
Jazyk: angličtina
Zdroj: Current opinion in pharmacology [Curr Opin Pharmacol] 2019 Dec; Vol. 49, pp. 95-101. Date of Electronic Publication: 2019 Nov 12.
DOI: 10.1016/j.coph.2019.10.004
Abstrakt: Diseases where fibrosis plays a major role accounts for enormous morbidity and mortality and yet we have very little in our therapeutic arsenal despite decades of research and clinical trials. Our understanding of fibrosis biology is primarily built on data generated in conventional mono-culture or co-culture systems and in vivo model systems. While these approaches have undoubtedly enhanced our understanding of basic mechanisms, they have repeatedly failed to translate to clinical benefit. Recently, there had been a push to generate more physiologically relevant platforms to study fibrosis and identify new therapeutic targets. Here we review the state-of-the-art regarding the development and application of 3D complex cultures, bio-printing and precision cut slices to study pulmonary, hepatic and renal fibrosis.
(Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: